Department of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, University of Texas at Tyler, Tyler, TX 75799, USA.
Nanoscale. 2024 Sep 12;16(35):16652-16663. doi: 10.1039/d4nr02191f.
Extracellular vesicles (EVs) have gained widespread interest due to their potential in the diagnosis and treatment of inflammation, autoimmune diseases, and cancers. EVs are lipidic vesicles comprising vesicles of endosomal origin called exosomes, microvesicles from membrane shedding, and apoptotic bodies from programmed cell death membrane blebbing that carry complex sets of cargo from their cells of origin, including proteins, lipids, mRNA, and DNA. EVs are rich in integrin proteins that facilitate intrinsic cellular communication to deliver their cargo contents and can also be used as biomarkers to study respective cellular conditions. Within this background, we hypothesized that when these EVs are hybridized with synthetic liposomes, it would help navigate the hybrid construct in the complex biological environment to find its target. Toward this endeavor, we have hybridized a synthetic liposome with EVs (herein called LEVs) derived from mouse breast cancer (4T1 tumors) cells and incorporated a rhodamine-B/near-infrared fluorescent dye to investigate their potential for cellular targeting and tumor delivery. Using membrane extrusion, we have successfully hybridized both entities resulting in the formation of LEVs and characterized their colloidal properties and stability over a period. While EVs are broadly dispersed nano- and micron-sized vesicles, LEVs are engineered as monodispersed with an average hydrodynamic size of 140 ± 5. Using immunoblotting and ELISA, we monitored and quantified the EV-specific protein CD63 and other characteristic proteins such as CD9 and CD81, which were taken as a handle to ensure the reproducibility of EVs and thus LEVs. These LEVs were further challenged with mice bearing orthotopic 4T1 breast tumors and the LEV uptake was found to be maximum in tumors and organs like the liver, spleen, and lungs when compared to control PEGylated liposomes in live animal imaging. Likewise, the constructs were capable of finding lung metastasis as observed in imaging. We anticipate that this study can open avenues for drug delivery solutions that are superior in target recognition.
细胞外囊泡 (EVs) 因其在炎症、自身免疫性疾病和癌症的诊断和治疗中的潜力而受到广泛关注。EVs 是由内体起源的囊泡(称为外泌体)、膜脱落的微泡和程序性细胞死亡膜起泡的凋亡体组成的脂质囊泡,它们从其起源细胞携带复杂的货物,包括蛋白质、脂质、mRNA 和 DNA。EVs 富含整合素蛋白,这些蛋白有助于内在细胞通讯以传递其货物内容物,并且还可以用作生物标志物来研究相应的细胞状态。在此背景下,我们假设当这些 EVs 与合成脂质体杂交时,它将有助于在复杂的生物环境中引导杂交构建体找到其靶标。为此,我们已经将合成脂质体与源自小鼠乳腺癌 (4T1 肿瘤) 细胞的 EVs(在此称为 LEVs)杂交,并掺入了罗丹明 B/近红外荧光染料,以研究它们用于细胞靶向和肿瘤递药的潜力。通过膜挤压,我们成功地杂交了这两种实体,从而形成了 LEVs,并在一段时间内对其胶体性质和稳定性进行了表征。虽然 EVs 是广泛分散的纳米和微米大小的囊泡,但 LEVs 被设计为单分散体,平均水动力直径为 140±5nm。通过免疫印迹和 ELISA,我们监测和量化了 EV 特异性蛋白 CD63 和其他特征蛋白,如 CD9 和 CD81,这些蛋白被用作确保 EVs 因此 LEVs 重现性的把手。这些 LEVs 进一步用患有原位 4T1 乳腺癌的小鼠进行了挑战,与对照 PEG 化脂质体相比,在活体动物成像中发现 LEV 在肿瘤和肝脏、脾脏和肺部等器官中的摄取量最大。同样,在成像中观察到这些构建体能够发现肺转移。我们预计这项研究可以为药物输送解决方案开辟途径,这些解决方案在目标识别方面更优越。